论文部分内容阅读
目的:研究马来酸罗格列酮对去势大鼠骨微结构的影响。方法:21只24周龄Wistar大鼠双侧卵巢切除,随机分为对照组、罗格列酮A(RA)组、罗格列酮B(RB)组,每组7只。RA组、RB组每只大鼠分别给予马来酸罗格列酮0.35 mg/d、0.70 mg/d(以生理盐水溶解灌胃),对照组以相同体积生理盐水灌胃。给药4周后使用micro-CT分别测定股骨、胫骨、椎骨的骨量/组织量(BV/TV)、骨小梁数目(Tb.N)、骨小梁厚度(Tb.Th)、骨小梁分离度(Tb.Sp)、骨表面积/骨量(BS/BV)。结果:与对照组相比,RA组及RB组各部位(股骨、胫骨、椎骨)Tb.N、Tb.Th和BS/BV(RA组胫骨除外)均减少(P<0.05或P<0.01);胫骨、椎骨Tb.Sp增加(P<0.05),股骨Tb.Sp无改变(P>0.05);各部位BV/TV差异无统计学意义(P>0.05)。上述检测指标在RA组与RB之间差异无统计学意义(P>0.05)。结论:使用罗格列酮后,骨微结构受到损伤,且主要集中于松质骨。
Objective: To study the effect of rosiglitazone maleate on the microstructure of ovariectomized rats. Methods: Twenty-one Wistar rats of 24 weeks old were ovariectomized. They were randomly divided into control group, rosiglitazone A (RA) group and rosiglitazone B (RB) group. Rats in RA group and RB group were given rosiglitazone maleate 0.35 mg / d and 0.70 mg / d respectively (dissolved in physiological saline), and the control group was given gavage with the same volume of physiological saline. Four weeks after the administration, the bone mass / tissue volume (BV / TV), trabecular number (Tb.N), trabecular thickness (Tb.Th), bone size Beam resolution (Tb.Sp), bone surface area / bone mass (BS / BV). Results: Compared with the control group, Tb.N, Tb.Th and BS / BV (except tibia in RA group) decreased in all groups (P <0.05 or P <0.01) Tb.Sp in tibia and vertebrae increased (P <0.05), and Tb.Sp in femur did not change (P> 0.05). There was no significant difference in BV / TV between the two groups (P> 0.05). There was no significant difference in the above indexes between RA and RB (P> 0.05). Conclusion: After using rosiglitazone, the microstructure of the bone is damaged, and the main focus is on cancellous bone.